Gilead invests another $320M in Arcus as partners rehash their TIGIT pact

Gilead is further betting on its partner Arcus Biosciences by infusing the California biotech with $320 million, but the duo is also adjusting their pact to leave out a Phase III.

The equity investment comes at $21 per share $RCUS, a 37%…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks